News
EQS-News: Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68Ga-PentixaFor in Hypertension
Carsten Stolz to leave the Baloise Group as of 31 December 2025
Swiss Prime Site acquires modern office property in Zurich
.jpg?locale=us)
Coinbase to Participate in Goldman Sachs 2025 Financial Services Conference
Coinbase Global, Inc. announced today that Alesia Haas, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs 2025 Financial Services Conference on Tuesday, December 9
HSBC Commits $4 Million to Propel Resilient Job Growth and Strengthen Urban Communities
HSBC Bank USA announced today that it has allocated nearly $4 million for philanthropic causes to eight national and local non-profit organizations that are creating resilient employment pathways
EQS-Adhoc: Vulcan Energy Resources Limited: €2,200 million (A$3,929 million) financing package secured to fully fund Vulcan Ener-gy’s Phase One Lionheart Project
Fuller, Smith & Turner PLC: Transaction in own shares
Funding Circle Holdings plc: POS-Transaction in Own Shares
The New York Times Company's President and Chief Executive Officer Meredith Kopit Levien to Participate in the UBS Global Media and Telecom Conference
The New York Times Company (NYSE: NYT) announced today that it will participate in the UBS Global Media and Telecom Conference on Tuesday, December 9, 2025, in New York City.
Meredith Kopit
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Molina Healthcare
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH) and reminds investors of the
Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Form 8.3 - The Vanguard Group, Inc.: Greencore Group plc
Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the
Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc